Baiyunshan (00874): Subsidiary's Pharmaceutical Production License Amended

Stock News
02/02

Baiyunshan (00874) announced that its subsidiary, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd., has received a Pharmaceutical Production License approved and issued by the Guangdong Provincial Medical Products Administration. The license approves Qixing Pharmaceutical's request to add a new entrusted production address for the manufacturing of Xuhanting Granules (Sugar-Free Type), which it has outsourced to the Baiyunshan Pharmaceutical General Factory, a subsidiary of Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., based on the original outsourcing production address. This addition of a new entrusted production address for the manufacturing of Xuhanting Granules (Sugar-Free Type) by Qixing Pharmaceutical, building upon the original outsourcing arrangement with Baiyunshan Pharmaceutical General Factory, is beneficial for increasing production capacity, enhancing manufacturing efficiency, and meeting market demand. The acquisition of this Pharmaceutical Production License is not expected to have a material impact on the company's current period performance.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10